Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors

GlobeNewswire August 29, 2017

Genmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple Myeloma

GlobeNewswire August 24, 2017

Genmab Announces Financial Results for the First Half of 2017

GlobeNewswire August 9, 2017

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017

GlobeNewswire July 18, 2017

Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

GlobeNewswire June 16, 2017

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

GlobeNewswire June 16, 2017

Genmab Announces Plans for New Studies of Daratumumab

GlobeNewswire May 17, 2017

Genmab Announces Financial Results for the First Quarter of 2017

GlobeNewswire May 10, 2017

Genmab Announces New Phase III Combination Study of Daratumumab in Multiple Myeloma

GlobeNewswire April 28, 2017

Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma

GlobeNewswire April 28, 2017

Phase II Study of Daratumumab in Non-Hodgkin’s Lymphoma Will Not Proceed to Stage 2 of Trial

GlobeNewswire March 30, 2017

Grant of Restricted Stock Units to two new Board Members and Grant of Restricted Stock Units and Warrants to the new Member of Management in Genmab

GlobeNewswire March 29, 2017

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

GlobeNewswire March 28, 2017

CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma

GlobeNewswire February 24, 2017

Genmab 2016 Annual Report

GlobeNewswire February 22, 2017

Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer

GlobeNewswire February 8, 2017

Genmab Announces Updated 2016 Financial Guidance

GlobeNewswire February 6, 2017

Genmab Announces 2016 Net Sales Figures for DARZALEX® (Daratumumab)

GlobeNewswire January 24, 2017

Genmab Achieves USD 25 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

GlobeNewswire January 6, 2017

Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) for Relapsed Multiple Myeloma and Updates Financial Guidance

GlobeNewswire November 21, 2016